These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 33444532)
1. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. Choi WM; Choi J; Wong GL; Han S; Lim YS Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532 [No Abstract] [Full Text] [Related]
2. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. Lee HA; Seo YS; Kim SU Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178 [No Abstract] [Full Text] [Related]
3. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir? Kamal F; Khan MA Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182 [No Abstract] [Full Text] [Related]
4. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B". Papatheodoridis G; Sypsa V; Lampertico P J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659 [No Abstract] [Full Text] [Related]
5. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply. Pol S; Luzivika Nzinga C; Fontaine H; Carrat F; Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398 [No Abstract] [Full Text] [Related]
6. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Lampertico P; Papatheodoridis GV Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425 [No Abstract] [Full Text] [Related]
7. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228 [TBL] [Abstract][Full Text] [Related]
8. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. Wen Z; Feng Y; Yan X J Hepatol; 2021 Jan; 74(1):245-246. PubMed ID: 33008623 [No Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding. Dore GJ; Danta M; Matthews GV Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1028-1029. PubMed ID: 33007227 [No Abstract] [Full Text] [Related]
10. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. Ha I; Chung JW; Jang ES; Jeong SH; Kim JW J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B. Kamal F; Khan MA; Ahmed A; Nair S Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745 [No Abstract] [Full Text] [Related]
13. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred? van Erpecum KJ; Sonneveld MJ Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149 [No Abstract] [Full Text] [Related]
14. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Pol S; Aliment Pharmacol Ther; 2021 Mar; 53(5):616-629. PubMed ID: 33464621 [TBL] [Abstract][Full Text] [Related]
15. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients. Wang JG; Chen R; Wang LC Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238 [No Abstract] [Full Text] [Related]
16. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply. Tseng CH; Hsu YC; Nguyen MH Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87-88. PubMed ID: 33444533 [No Abstract] [Full Text] [Related]
17. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply. Pol S; Lusivika Nzinga C; Carrat F Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235 [No Abstract] [Full Text] [Related]
18. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857 [TBL] [Abstract][Full Text] [Related]
19. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Teng YX; Li MJ; Xiang BD; Zhong JH Gut; 2020 Oct; 69(10):1900-1902. PubMed ID: 31843789 [No Abstract] [Full Text] [Related]
20. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]